Microsecond Pulsing Laser for Choroidal Neovascularization Associated with Central Serous Chorioretinopathy.

IF 1.7 4区 医学 Q3 OPHTHALMOLOGY Current Eye Research Pub Date : 2024-10-23 DOI:10.1080/02713683.2024.2419667
Dmitrii S Maltsev, Alexei N Kulikov, Alexander S Vasiliev, Alina A Kazak, Yana A Kalinicheva, Jay Chhablani
{"title":"Microsecond Pulsing Laser for Choroidal Neovascularization Associated with Central Serous Chorioretinopathy.","authors":"Dmitrii S Maltsev, Alexei N Kulikov, Alexander S Vasiliev, Alina A Kazak, Yana A Kalinicheva, Jay Chhablani","doi":"10.1080/02713683.2024.2419667","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the efficacy and safety of microsecond pulsing laser therapy (MLT) in the management of central serous chorioretinopathy (CSCR) complicated by choroidal neovascularization (CNV).</p><p><strong>Methods: </strong>Patients with CSCR complicated by CNV defined as the presence of characteristic OCT angiography features were randomly assigned to either study or control group. All patients of the study group underwent MLT targeting CNV area using navigated laser system followed by at least 6-month follow-up. Sham treatment was performed in the control group. No other treatment or anti-VEGF therapy was used during the follow-up. Main outcome measure was complete resolution of subretinal fluid at the end of follow-up.</p><p><strong>Results: </strong>Twenty-three eyes (13 males and 10 females, mean age 58.2 ± 8.0 years) with a mean CNV area 0.62 ± 0.77 mm<sup>2</sup> were included in the study group. Fourteen (60.9%) patients achieved complete resolution of SRF, five (21.7%) patients demonstrated some reduction of SRF, and four (17.4%) patients demonstrated no improvement after MLT in the study group. Twelve eyes (8 males and 4 females, mean age 59.8 ± 4.6 years) were included in the control group where none of them demonstrated resolution of SRF at the end of the follow-up (<i>p</i> = 0.0018 compared to the study group). No adverse effects, such as changes of CNV size, deterioration of exudation, or decline in visual acuity were observed in the study group.</p><p><strong>Conclusion: </strong>Microsecond pulsing laser is an effective and safe option for the treatment of CSCR complicated by relatively small CNV and achieves complete resolution of SRF in 61% of cases.</p>","PeriodicalId":10782,"journal":{"name":"Current Eye Research","volume":" ","pages":"1-10"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Eye Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02713683.2024.2419667","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To analyze the efficacy and safety of microsecond pulsing laser therapy (MLT) in the management of central serous chorioretinopathy (CSCR) complicated by choroidal neovascularization (CNV).

Methods: Patients with CSCR complicated by CNV defined as the presence of characteristic OCT angiography features were randomly assigned to either study or control group. All patients of the study group underwent MLT targeting CNV area using navigated laser system followed by at least 6-month follow-up. Sham treatment was performed in the control group. No other treatment or anti-VEGF therapy was used during the follow-up. Main outcome measure was complete resolution of subretinal fluid at the end of follow-up.

Results: Twenty-three eyes (13 males and 10 females, mean age 58.2 ± 8.0 years) with a mean CNV area 0.62 ± 0.77 mm2 were included in the study group. Fourteen (60.9%) patients achieved complete resolution of SRF, five (21.7%) patients demonstrated some reduction of SRF, and four (17.4%) patients demonstrated no improvement after MLT in the study group. Twelve eyes (8 males and 4 females, mean age 59.8 ± 4.6 years) were included in the control group where none of them demonstrated resolution of SRF at the end of the follow-up (p = 0.0018 compared to the study group). No adverse effects, such as changes of CNV size, deterioration of exudation, or decline in visual acuity were observed in the study group.

Conclusion: Microsecond pulsing laser is an effective and safe option for the treatment of CSCR complicated by relatively small CNV and achieves complete resolution of SRF in 61% of cases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
微秒脉冲激光治疗与中央浆液性脉络膜视网膜病变相关的脉络膜新生血管。
目的:分析微秒脉冲激光疗法(MLT)治疗并发脉络膜新生血管(CNV)的中心性浆液性脉络膜视网膜病变(CSCR)的有效性和安全性:方法:将出现特征性 OCT 血管造影特征、并发 CNV 的 CSCR 患者随机分配到研究组或对照组。研究组的所有患者均使用导航激光系统针对 CNV 区域进行了 MLT 治疗,并进行了至少 6 个月的随访。对照组采用假治疗。随访期间未使用其他治疗或抗血管内皮生长因子疗法。主要结果指标为随访结束时视网膜下积液完全消退:研究组共纳入 23 只眼睛(13 男 10 女,平均年龄 58.2 ± 8.0 岁),CNV 平均面积为 0.62 ± 0.77 平方毫米。研究组中有 14 名(60.9%)患者的 SRF 完全消退,5 名(21.7%)患者的 SRF 有所减退,4 名(17.4%)患者的情况在 MLT 后没有改善。对照组中有 12 只眼睛(8 男 4 女,平均年龄为 59.8 ± 4.6 岁)在随访结束时均未出现 SRF 消退(与研究组相比,P = 0.0018)。研究组未观察到CNV大小变化、渗出恶化或视力下降等不良反应:结论:微秒脉冲激光是治疗并发相对较小 CNV 的 CSCR 的一种有效而安全的方法,61% 的病例可完全消除 SRF。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Eye Research
Current Eye Research 医学-眼科学
CiteScore
4.60
自引率
0.00%
发文量
163
审稿时长
12 months
期刊介绍: The principal aim of Current Eye Research is to provide rapid publication of full papers, short communications and mini-reviews, all high quality. Current Eye Research publishes articles encompassing all the areas of eye research. Subject areas include the following: clinical research, anatomy, physiology, biophysics, biochemistry, pharmacology, developmental biology, microbiology and immunology.
期刊最新文献
Relationship of Angle Kappa with Ocular Parameters using Swept-Source Ocular Coherence Tomography in Cataract Surgery Patients. Selective Gamma-Secretase Inhibition by CHF5074 Attenuates Inflammation and Neovascularization in a Murine Model of Choroidal Neovascularization. Expression of PAX6 and Keratocyte-Characteristic Markers in Human Limbal Stromal Cells of Congenital Aniridia and Healthy Subjects, In Vitro. Brolucizumab and Platelet Activation and Reactivity. Correction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1